Search 

Meet Cancer Research Horizons at the UK Pavilion (Hall B, Stand 2348).

Cancer Research Horizons is the innovation arm of Cancer Research UK – the world's largest charitable funder of cancer research. We bring together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.

To date, we've played an instrumental role in forming over 60 spin-out companies. We've helped bring 11 cancer drugs to market, borne out of Cancer Research UK's pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients across the world. With access to Cancer Research UK's network of 4000 exceptional researchers and clinicians, and £300+ million of annual research spend, we're a powerful partner in the fight to conquer cancer.

Meet The Cell and Gene Therapy Catapult at the UK Pavilion (Hall B, Stand 2348). 

The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. With over 400 experts covering all aspects of advanced therapies, it applies its unique capabilities and assets, collaborates with academia, industry and healthcare providers to develop new technology and innovation. The Cell and Gene Therapy Catapult works with Innovate UK. 

Meet Clyde Biosciences at the UK Pavilion (Hall B, Stand 2348).

Clyde Biosciences specialises in measuring and interpreting drug effects on cardiac cell function at clinically relevant doses. The company's proprietary technology combines a rang of human stem cell and other relevant in vitro phenotypes with a sensitive, data-rich measurement system and expert interpretation. The platform is demonstrable capable of screening-level throughout providing a more complete assessment of cardiovascular efficay and safety with in vivo and clinical preditability. 

Meet Cumulus Neuroscience at the UK Pavilion (Hall B, Stand 2348). 

Cumulus Neuroscience provides a reliable real-world multimodal digital data acquisition and analytics platform and end-to-end services and solutions for CNS clinical trials. Our platform is designed to be the gold-standard for CNS assessments, providing the critical data and insight needed for faster, more robust and cost-effective clinical trials that improve the delivery of new therapies to patients. We provide frequent at-home acquisition, combining neurophysiological monitoring (EEG) time-linked with a range of assessment tools, including cognition, mood, language and sleep. The frequent remote assessment significantly lowers patient burden and allows aggregation of multiple sessions to account for day-to-day cognitive fluctuation. Cumulus was formed in collaboration with leading global pharmaceutical companies to meet the industry’s complex clinical trial needs with a pharma advisory consortium, and Cumulus’ platform is currently deployed in clinical trials for neurodegeneration and neuropsychiatric diseases.